131 related articles for article (PubMed ID: 36071100)
1. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.
Kubasch AS; Giagounidis A; Metzgeroth G; Jonasova A; Herbst R; Diaz JMT; De Renzis B; Götze KS; Huetter-Kroenke ML; Gourin MP; Slama B; Dimicoli-Salazar S; Cony-Makhoul P; Laribi K; Park S; Jersemann K; Schipp D; Metzeler KH; Tiebel O; Sockel K; Gloaguen S; Mies A; Chermat F; Thiede C; Sapena R; Schlenk RF; Fenaux P; Platzbecker U; Adès L
Leukemia; 2022 Oct; 36(10):2519-2527. PubMed ID: 36071100
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
Sekeres MA; Giagounidis A; Kantarjian H; Mufti GJ; Fenaux P; Jia C; Yang AS; Platzbecker U
Br J Haematol; 2014 Nov; 167(3):337-45. PubMed ID: 25039607
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
Kantarjian H; Fenaux P; Sekeres MA; Becker PS; Boruchov A; Bowen D; Hellstrom-Lindberg E; Larson RA; Lyons RM; Muus P; Shammo J; Siegel R; Hu K; Franklin J; Berger DP
J Clin Oncol; 2010 Jan; 28(3):437-44. PubMed ID: 20008626
[TBL] [Abstract][Full Text] [Related]
4. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial.
Lee JW; Lee SE; Jung CW; Park S; Keta H; Park SK; Kim JA; Oh IH; Jang JH
Lancet Haematol; 2019 Nov; 6(11):e562-e572. PubMed ID: 31474546
[TBL] [Abstract][Full Text] [Related]
5. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.
Giagounidis A; Mufti GJ; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Hu K; Woodard P; Yang AS; Kantarjian HM
Cancer; 2014 Jun; 120(12):1838-46. PubMed ID: 24706489
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
Kantarjian HM; Giles FJ; Greenberg PL; Paquette RL; Wang ES; Gabrilove JL; Garcia-Manero G; Hu K; Franklin JL; Berger DP
Blood; 2010 Oct; 116(17):3163-70. PubMed ID: 20631375
[TBL] [Abstract][Full Text] [Related]
8. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
Fenaux P; Muus P; Kantarjian H; Lyons RM; Larson RA; Sekeres MA; Becker PS; Orejudos A; Franklin J
Br J Haematol; 2017 Sep; 178(6):906-913. PubMed ID: 28616874
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.
Greenberg PL; Garcia-Manero G; Moore M; Damon L; Roboz G; Hu K; Yang AS; Franklin J
Leuk Lymphoma; 2013 Feb; 54(2):321-8. PubMed ID: 22906162
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
[TBL] [Abstract][Full Text] [Related]
11. Up-front Treatment With Romiplostim in Children With Acquired Bone Marrow Failure: A Single Institutional Pediatric Case Series.
Al-Huniti A; Rathi N; Modi A; Bhagavathi S; Mitten R; Sharathkumar AA
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e431-e435. PubMed ID: 32341259
[TBL] [Abstract][Full Text] [Related]
12. Romiplostim dose-response in patients with myelodysplastic syndromes.
Perez Ruixo JJ; Doshi S; Wang YM; Mould DR
Br J Clin Pharmacol; 2013 Jun; 75(6):1445-54. PubMed ID: 23171070
[TBL] [Abstract][Full Text] [Related]
13. Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial.
Platzbecker U; Sekeres MA; Kantarjian H; Giagounidis A; Mufti GJ; Jia C; Yang AS; Fenaux P
Leukemia; 2014 Dec; 28(12):2418-21. PubMed ID: 25179731
[No Abstract] [Full Text] [Related]
14. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.
Wang ES; Lyons RM; Larson RA; Gandhi S; Liu D; Matei C; Scott B; Hu K; Yang AS
J Hematol Oncol; 2012 Nov; 5():71. PubMed ID: 23190430
[TBL] [Abstract][Full Text] [Related]
15. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
[TBL] [Abstract][Full Text] [Related]
17. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
[TBL] [Abstract][Full Text] [Related]
18. Romiplostim.
Kuter DJ
Cancer Treat Res; 2011; 157():267-88. PubMed ID: 21052962
[TBL] [Abstract][Full Text] [Related]
19. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.
Sekeres MA; Kantarjian H; Fenaux P; Becker P; Boruchov A; Guerci-Bresler A; Hu K; Franklin J; Wang YM; Berger D
Cancer; 2011 Mar; 117(5):992-1000. PubMed ID: 20945323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
